Cancer-associated neutropenic fever: Clinical outcome and economic costs of emergency department care

Oncologist

Volumn 12, Issue 8, 2007, Pages 1019-1026

  Courtney, D Mark ^a   Aldeen, Amer Z ^a   Gorman, Stephen M ^a   Handler, Jonathan A ^a   Trifilio, Steven M ^b   Parada, Jorge P ^c   Yarnold, Paul R ^a   Bennett, Charles L ^a,d,e  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

^d JESSE BROWN VA MEDICAL CENTER   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cancer induced neutropenia; Emergency department; Febrile neutropenia; Neutropenic fever

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT;

ARTICLE; BLOOD CULTURE; CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; COST BENEFIT ANALYSIS; DIAGNOSTIC TEST; DISEASE ASSOCIATION; ECONOMIC ASPECT; EMERGENCY WARD; FEBRILE NEUTROPENIA; FEVER; HEALTH SERVICE; HUMAN; INTENSIVE CARE UNIT; MEDICAL RECORD; OUTCOME ASSESSMENT; PATIENT INFORMATION; PRIORITY JOURNAL;

ADULT; AGED; COSTS AND COST ANALYSIS; EMERGENCY TREATMENT; FEMALE; FEVER; HEALTH CARE COSTS; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; TREATMENT OUTCOME;

EID: 34548431722     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.12-8-1019     Document Type: Article

References (10)

1. Bodey GP, Buckley M, Sathe YS et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328-340.
2. Talcott JA, Siegel RD, Finberg R et al. Risk assessment in cancer patients with fever and neutropenia: A prospective, two-center validation of a prediction rule. J Clin Oncol 1992;10:316-322.
3. Klastersky J, Paesmans M, Rubenstein EB et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000;18:3038-3051.
4. Klastersky J. Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis 2004;39(suppl 1):S32-S37.
5. Perrone J, Hollander JE, Datner EM. Emergency department evaluation of patients with fever and chemotherapy-induced neutropenia. J Emerg Med 2004;27:115-119.
6. Mandell LA, Bartlett JG, Dowell SF et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003;37:1405-1433.
7. Lyman GH, Kuderer N, Greene J et al. The economics of febrile neutropenia: Implications for the use of colony-stimulating factors. Eur J Cancer 1998;34:1857-1864.
8. Cosler LE, Sivasubramaniam V, Agboola O et al. Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy. Value Health 2005;8:47-52.
9. Adams JR, Angelotta C, Bennett CL. When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective? J Clin Oncol 2006;24:2975-2977.
10. Smith TJ, Khatcheressian J, Lyman GH et al. 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-3205.